Intrinsic Cell-penetrating Activity Propels Omomyc from Proof of Concept to Viable Anti-MYC Therapy
Overview
Science
Authors
Affiliations
Inhibiting MYC has long been considered unfeasible, although its key role in human cancers makes it a desirable target for therapeutic intervention. One reason for its perceived undruggability was the fear of catastrophic side effects in normal tissues. However, we previously designed a dominant-negative form of MYC called Omomyc and used its conditional transgenic expression to inhibit MYC function both in vitro and in vivo. MYC inhibition by Omomyc exerted a potent therapeutic impact in various mouse models of cancer, causing only mild, well-tolerated, and reversible side effects. Nevertheless, Omomyc has been so far considered only a proof of principle. In contrast with that preconceived notion, here, we show that the purified Omomyc mini-protein itself spontaneously penetrates into cancer cells and effectively interferes with MYC transcriptional activity therein. Efficacy of the Omomyc mini-protein in various experimental models of non-small cell lung cancer harboring different oncogenic mutation profiles establishes its therapeutic potential after both direct tissue delivery and systemic administration, providing evidence that the Omomyc mini-protein is an effective MYC inhibitor worthy of clinical development.
MYC in cancer: from undruggable target to clinical trials.
Whitfield J, Soucek L Nat Rev Drug Discov. 2025; .
PMID: 39972241 DOI: 10.1038/s41573-025-01143-2.
Xu H, Ma Y, Li H, Song X, Liu Y, Mierzhakenmu Z Breast Cancer (Dove Med Press). 2024; 16:855-866.
PMID: 39655230 PMC: 11626956. DOI: 10.2147/BCTT.S487070.
Ellenbroek B, Kahler J, Arella D, Lin C, Jespers W, Zuger E Angew Chem Int Ed Engl. 2024; 64(4):e202416082.
PMID: 39315681 PMC: 11753601. DOI: 10.1002/anie.202416082.
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.
PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.
Defining neuroblastoma: From origin to precision medicine.
Sainero-Alcolado L, Sjoberg Bexelius T, Santopolo G, Yuan Y, Liano-Pons J, Arsenian-Henriksson M Neuro Oncol. 2024; 26(12):2174-2192.
PMID: 39101440 PMC: 11630532. DOI: 10.1093/neuonc/noae152.